In Silico and In Vitro Evaluation of Hydrazone-Based Kinase Inhibitors for Anti-Proliferative Activity in Colorectal Cancer Cell Lines
DOI:
https://doi.org/10.5281/zenodo.22664404Keywords:
hydrazone, kinase inhibitor, molecular docking, colorectal cancer, structure-activity relationshipAbstract
Background: Colorectal cancer remains a leading cause of cancer mortality worldwide, and resistance to existing kinase-directed
therapies limits durable disease control, motivating continued search for new small-molecule chemotypes with kinase-inhibitory
anti-proliferative activity. Objective: This case study designed, computationally prioritized, and experimentally evaluated a focused
hydrazone-based small-molecule series as candidate kinase inhibitors with anti-proliferative activity against colorectal cancer cell
lines. Methods: Eighteen hydrazone derivatives were docked against the ATP-binding sites of EGFR and VEGFR-2 using AutoDock
Vina, and drug-likeness/ADMET parameters were predicted using SwissADME. Eight compounds spanning the docking-score and
heterocyclic-substitution range were synthesized and evaluated by MTT assay for 72-hour anti-proliferative activity against
HCT116, HT-29, and SW480 colorectal cancer cell lines; the lead compound was further characterized by flow cytometric cell-cycle
and Annexin V apoptosis analysis in HCT116 cells. Findings: Compounds bearing electron-withdrawing para-aryl substituents
consistently showed predicted EGFR hinge-region hydrogen bonding and superior measured potency, with the lead compound, HZ7,
achieving IC50 values of 6.2-11.4 uM across the three cell lines, comparable to the reference kinase inhibitor sorafenib. HZ7 induced
concentration- and time-dependent G2/M cell-cycle arrest progressing to caspase-dependent apoptosis, with the sub-G1 apoptotic
fraction rising from 3.1% in controls to 28.6% at 48 hours. HCT116 was consistently the most sensitive cell line and SW480 the least
sensitive across the series. Conclusions: A structure-based docking and in silico ADMET pipeline successfully prioritized a hydrazone
lead compound with reproducible, mechanistically coherent anti-proliferative activity against colorectal cancer cell lines,
supporting the hydrazone scaffold as a tractable chemotype for further kinase-targeted anti-colorectal-cancer development
pending confirmatory biochemical and in vivo evaluation.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer, 17:48, DOI:10.1186/s12943-018-0804-2.
Mortazavi M, Divar M, Damghani T, Moosavi F, Saso L, Pirhadi S, Khoshneviszadeh M, Edraki N, Firuzi O (2022) Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. Frontiers in Chemistry, 10:969559, DOI:10.3389/fchem.2022.969559.
Rollas S, Küçükgüzel SG (2007) Biological activities of hydrazone derivatives. Molecules, 12(8):1910-1939, DOI:10.3390/12081910.
Farghaly TA, Abbas EMH, Al-Soliemy AM, Sabour R, Shaaban MR (2022) Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: design, synthesis, biological evaluation and molecular docking studies. Bioorganic Chemistry, 121:105684, DOI:10.1016/j.bioorg.2022.105684.
Nasr T, Bondock S, Youns M (2014) Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. European Journal of Medicinal Chemistry, 76:539-548, DOI:10.1016/j.ejmech.2014.02.026.
Lu JX, Lan HR, Zeng D, Song JY, Hao YT, Xing AP, Shen A, Yuan J (2025) Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives. RSC Advances, 15(1):231-243, DOI:10.1039/d4ra06954d.
Bawazir WA, Ali TE, Alsolimani AK, Assiri MA, Shati AA, Alfaifi MY, Elbehairi SEI (2025) Novel ethyl 2-hydrazineylidenethiazolidin-5-ylidene acetate clubbed with coumarinylthiazolyl pyrazole system as potential VEGFR-2 inhibitors and apoptosis inducer: synthesis, cytotoxic evaluation, cell cycle, autophagy, in silico ADMET and molecular docking studies. RSC Advances, 15(7):4829-4846, DOI:10.1039/d5ra00250h.
Patil S, Kumar MM, Palvai S, Sengupta P, Basu S (2018) Impairing powerhouse in colon cancer cells by hydrazide-hydrazone-based small molecule. ACS Omega, 3(2):1470-1481, DOI:10.1021/acsomega.7b01512.
Castrillón-López W, Herrera-Ramírez A, Moreno-Quintero G, Coa JC, Naranjo TW, Cardona-Galeano W (2022) Resveratrol/hydrazone hybrids: synthesis and chemopreventive activity against colorectal cancer cells. Pharmaceutics, 14(11):2278, DOI:10.3390/pharmaceutics14112278.
Mermer A, Bayrak AM, Bolat ZB, Ramadan RM, Dilsiz N (2026) Synthesis, characterization, DFT analysis, molecular docking and anticancer investigations in colorectal carcinoma of a novel pyrazole-hydrazone zinc(II) complex. Scientific Reports, 16:6391, DOI:10.1038/s41598-026-35664-6.
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7:42717, DOI:10.1038/srep42717.
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2):455-461, DOI:10.1002/jcc.21334.
Panwar V, Rohila Y, Singh A, Meenakshi, Singh B, Gupta MK, Garg M, Kumar D (2025) Design, synthesis, in silico, anticancer evaluations of N-acylhydrazone derivatives as STAT3 inhibitors. Future Medicinal Chemistry, 17(13):1509-1519, DOI:10.1080/17568919.2025.2527604.
Abulkhair HS, Turky A, Ghiaty A, Ahmed HEA, Bayoumi AH (2020) Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies. Bioorganic Chemistry, 100:103899, DOI:10.1016/j.bioorg.2020.103899.
Dilek Ö (2025) Comprehensive study of imidazole-based hydrazones: from design, synthesis, and characterization to in vitro and in silico antiproliferative activity analysis. Turkish Journal of Chemistry, 49(4):419-438, DOI:10.55730/1300-0527.3741.
Özil M, Önelge E, Emirik M, Acikalin Coskun K, Tutar Y (2026) Trifluoromethyl-benzimidazole-hydrazone derivatives as promising selective anticancer agents: synthesis, cytotoxicity, and molecular docking insights. Pharmaceuticals, 19(8):1270, DOI:10.3390/ph19081270.
Kumar R, Chauhan D, Singh VK, Kushwaha AK, Kushwaha D (2025) Design, synthesis, and in-silico studies of hydrazide-hydrazone linked coumarin glycoconjugates with possible antiproliferative activity. Carbohydrate Research, 556:109620, DOI:10.1016/j.carres.2025.109620.
Biliz Y, Hasdemir B, Başpınar Küçük H, Zaim M, Şentürk AM, Müdüroğlu Kırmızıbekmez A, Kara İ (2023) Novel N-acyl hydrazone compounds as promising anticancer agents: synthesis and molecular docking studies. ACS Omega, 8(22):20073-20084, DOI:10.1021/acsomega.3c02361.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2):55-63, DOI:10.1016/0022-1759(83)90303-4.
Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nature Protocols, 1(3):1458-1461, DOI:10.1038/nprot.2006.238.
